Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy and safety of MagnetOs.
Earlier this quarter, Kuros received CE Mark approval for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy...
Kuros Biosciences commenced an investigator-led multicenter study comparing MagnetOs bone graft substitute vs. autologous bone in posterolateral spinal fusion.
The blinded, controlled, randomized multicenter trial will enroll 100 patients in the Netherlands, starting in 2H18. The primary objective is to demonstrate non-inferiority in efficacy and safety of MagnetOs.
Earlier this quarter, Kuros received CE Mark approval for MagnetOs Putty as an osteoconductive, osteoinductive bone void filler inthe spine, extremities, pelvis, cranium, mandible and maxilla.
Copy to clipboard 
